Oral Semaglutide's Safety and Absorption Studied in Liver Impairment

Oral semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes. Understanding its pharmacokinetics (how the body processes the drug), safety, and tolerability is crucial, especially in populations with compromised organ function. This study aimed to determine how oral semaglutide behaves in individuals with varying degrees of liver function.

The provided clinical trial registration (NCT02016911) indicates the study was completed in January 2015, but specific results detailing the pharmacokinetics, safety, or tolerability of oral semaglutide in subjects with hepatic impairment were not included in this record. Therefore, quantitative data regarding drug exposure, such as Cmax (maximum concentration) or AUC (area under the curve), half-life, adverse event rates, or comparisons between groups with different degrees of liver function are not available here. The primary objective was to understand how liver function impacts the body's processing of oral semaglutide, a critical step for safe drug use and potential dose adjustments. Without the full study report, we cannot quantify any observed differences in drug exposure or adverse event rates between the mild, moderate, and severe hepatic impairment groups and the control group with normal hepatic function. The trial aimed to determine if hepatic impairment significantly alters semaglutide's metabolism or excretion.